Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder
The goals of these two phased studies (“R61” followed by “R33”) are to establish a biological signature of CBD’s putative therapeutic effects in SAD and its link to core SAD symptoms, to provide estimates of clinical effect sizes, and to provide safety and feasibility data to guide a future definitive RCT of CBD for SAD.
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
A dose-escalation phase (phase I) is added to determine RP2D. In phase I, 3 mg/kg dose were added in the dose escalation phase, including 6 patients to receive study drug at 3 mg/kg and Lu 177 vipivotide and 3 patients to receive Lu 177 vipivotide alone. Optional intermediate doses of 6 mg/kg and 1 mg/kg was proposed in case either 3 mg/kg or 10 mg/kg was found to have excess toxicity.DLT observation period updated to 28 days.Added Exploratory Objectives.Trial design has been updated to include dose escalation phase (phase I) and dose expansion phase (phase II).
Rapid Motion-Robust and Easy-to-Use Dynamic Contrast-Enhanced MRI for Liver Perfusion Quantification (Non-treatment cohort)
We propose to develop new rapid MRI techniques combining novel motion-robust sampling strategies and advanced reconstruction models to address these challenges.
Rapid Structure-Function MRI of the Lung for Post-COVID-19 Management
The objective of this application is to develop novel rapid free-breathing four-dimensional (4D=3D+time) lung MRI techniques that will enable non-invasive radiation-free evaluation of lung anatomy and pulmonary function in the longitudinal follow-ups of post-COVID-19 patients. This novel imaging framework could provide a unique opportunity to augment post-COVID care, particularly for identifying COVID-19-induced lung abnormality in a timely manner and for studying the longitudinal changes of lung anatomy and global/regional pulmonary function.
Reach Out Stay Strong Essentials for mothers of newborns (ROSE) Adaptation for Chinese American mothers
We are conducting a cultural adaptation and pilot study of a postpartum depression prevention intervention among pregnant Chinese American women. Once we establish feasibility and acceptability of the adapted intervention, we will conduct a pilot study. The study consists of focus groups, key-informant interviews, pre-intervention and post-inervetnion questionnaires, a debrief session, and a 7 session intervention.
Real Estate, Development & Facilities Design Guidelines | NYU Langone Health
NYU Langone has design guidelines for project managers, architects, and engineering teams.
Real Estate, Development & Facilities Procurement Opportunities | NYU Langone Health
NYU Langone offers procurement opportunities for various types of projects.
Reanimation Surgery for Facial Nerve Paralysis | NYU Langone Health
Surgeons at NYU Langone perform reanimation procedures to restore facial symmetry and reanimate facial muscles.
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA is at the treating physician’s discretion and independent from the decision to enroll the patient in the study. Adult patients who receive a prescription for REBYOTA to prevent rCDI are eligible to enroll according to the inclusion and exclusion criteria described below. Patients must enroll in the study between prescription and administration. This allows time for patients to enroll while still conducting the baseline measurement of patient-reported outcomes (CDI-DaySyms™) prior to administration. REBYOTAFor each patient, the current or presenting rCDI episode will be defined as the CDI episode just prior to receiving REBYOTA. If a patient receives REBYOTA more than once, the first dose will be used to define the presenting rCDI and to assess REBYOTA effectiveness.Baseline period will be defined as the time period between the date REBYOTA is prescribed and the date REBYOTA is administered.Data will be collected from patients’ medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, AEs, and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA administration.
Reconstruction for Head & Neck Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center can reconstruct bone and soft tissues after surgery for head and neck cancer.